Community-based delivery of HIV treatment in Cambodia
Implementation and Evaluation of a Community-Based Model for Delivery of Antiretroviral Therapy in Cambodia: A Quasi-Experimental Study
This study is testing a new way to deliver HIV treatment at home in Cambodia to see if it helps people stay in care and manage their health better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 4102 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | National University of Singapore Academic / other |
| Locations | 3 sites (Phnom Penh and 2 other locations) |
| Trial ID | NCT04766710 on ClinicalTrials.gov |
What this trial studies
This project aims to implement a community-based model for delivering antiretroviral therapy (ART) to improve retention in care and viral load suppression among people living with HIV in Cambodia. The model will utilize Community Action Workers (CAW) to engage with patients and provide ART closer to their homes, reducing the burden of frequent clinic visits. The study will be conducted across nine ART sites and will include a thorough evaluation plan to assess its effectiveness in the local context. The initiative builds on previous experiences and aims to adapt successful strategies to meet the specific needs of the Cambodian population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 15 years and older who have been receiving ART for at least one year and have demonstrated treatment success.
Not a fit: Patients who are unstable, mobile populations, or those with adverse drug reactions or opportunistic infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve access to HIV treatment and health outcomes for patients in Cambodia.
How similar studies have performed: Previous studies have indicated the effectiveness of community-based ART delivery models, suggesting a promising outlook for this approach in Cambodia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Receiving ART for at least one year. 2. No adverse drug reactions or ARV drug interactions requiring regular monitoring. 3. No suspected or confirmed tuberculosis, no other opportunistic infections, and not on any prophylaxis. 4. Not pregnant/breastfeeding (for women). 5. Having a good understanding of lifelong treatment and adherence to the medication. 6. Presenting with evidence of treatment success: two consecutive undetectable viral load measures (or, in the absence of viral load monitoring, CD4 counts above 200 cells/mm3 and objective adherence measure). 7. Aged ≥15 years. 8. On the first-line ARV regimen. Exclusion criteria 1. Unstable people living with HIV as defined above 2. Mobile populations
Where this trial is running
Phnom Penh and 2 other locations
- KHANA Center for Population Health Research — Phnom Penh, Cambodia (Recruiting)
- Cambodia Anti-Tuberculosis Association — Phnom Penh, Cambodia (Recruiting)
- National Center for Tuberculosis and Leprosy Control — Phnom Penh, Cambodia (Recruiting)
Study contacts
- Study coordinator: Siyan Yi, PhD
- Email: siyan@doctor.com
- Phone: 6587533823
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.